Avodart is an oral capsule used in adult men with benign prostatic hyperplasia, also called BPH or an enlarged prostate. It works by reducing the hormonal stimulation that contributes to prostate growth, which can improve urinary flow and reduce bothersome urinary symptoms over time.
Avodart is an oral capsule containing dutasteride for adult men with benign prostatic hyperplasia. It belongs to the 5-alpha-reductase inhibitor class.
Avodart is an oral capsule containing dutasteride. Dutasteride belongs to the 5-alpha-reductase inhibitor class and reduces hormonal stimulation that contributes to prostate growth.
Avodart belongs to the 5-alpha-reductase inhibitor class. This enzyme normally converts testosterone into dihydrotestosterone, abbreviated as DHT. DHT has a stronger effect than testosterone on prostate tissue and contributes to prostate enlargement in susceptible men.
Dutasteride inhibits both type 1 and type 2 forms of 5-alpha-reductase. This dual enzyme inhibition lowers DHT levels in the blood and within the prostate. As DHT stimulation falls, prostate tissue may gradually shrink and place less pressure on the urethra.
Avodart is a urology medication used for the treatment of benign prostatic hyperplasia in adult men. BPH is a non-cancerous enlargement of the prostate gland that may narrow the urethra and make bladder emptying harder. Symptoms may include a weak urine stream, hesitancy, straining, frequent urination, urgency, and waking at night to urinate.
The clinical aim is not only symptom relief. Reducing prostate volume can also lower the long-term likelihood of acute urinary retention and BPH-related surgery in suitable patients. Health Canada identifies dutasteride as a 5-alpha-reductase inhibitor used in men with symptomatic BPH and an enlarged prostate. [1]
Avodart is generally considered when prostate enlargement is clinically relevant and urinary symptoms affect daily life, sleep, travel, or confidence outside the home. It is not a fast-acting bladder-relaxing treatment. Its role is to address the hormonal driver of prostate enlargement gradually.
Symptoms that often lead to BPH assessment include:
A common mistake is expecting Avodart to act like an alpha-blocker. It does not usually provide immediate relief of urine flow symptoms, so stopping after a short trial can mean stopping before prostate-volume effects develop.
Another frequent error is splitting, chewing, or opening capsules. The capsule is designed to be swallowed intact. Damaging it can expose the mouth or throat to the contents and creates avoidable pregnancy exposure risk for others.
Other mistakes include:
Acute inability to urinate needs urgent medical care. Fever with urinary symptoms may indicate infection rather than routine BPH progression.
Avodart is not for you if:
Women who are pregnant or may become pregnant should not handle leaking capsules. Absorption through the skin may affect development of male fetal genitalia.
Blood donation may also be restricted during treatment and for a period after the final dose because dutasteride remains in the body for a long time. The product information for dutasteride outlines the pregnancy exposure concern, PSA considerations, and sexual adverse reactions. [2]
Avodart can cause sexual side effects, especially during the first months of treatment. Reduced libido, erectile dysfunction, reduced semen volume, and ejaculation changes are among the best-recognized effects of 5-alpha-reductase inhibition.
Breast tenderness or enlargement can also occur. A new breast lump, nipple discharge, or persistent breast pain needs clinical assessment rather than being dismissed as a routine side effect.
Some men experience no noticeable adverse effects. Others find sexual effects troublesome enough to reconsider treatment with their prescriber. Effects may improve with time, though they can persist in some people after treatment is stopped.
| Effect | Practical context |
|---|---|
| Reduced sexual desire | May emerge early in treatment and can affect interest in sex |
| Erectile difficulty | May be related to the medicine, BPH itself, age, vascular health, or other medicines |
| Ejaculation changes | Semen volume may decrease because DHT affects prostate and seminal-fluid function |
| Breast tenderness or enlargement | Less common, but persistent changes need assessment |
There are limits to what Avodart can do. It may reduce prostate size and lower progression risk, but it does not treat urinary symptoms caused by infection, bladder stones, prostate cancer, or neurological bladder disorders.
BPH treatment is chosen according to prostate size, symptom severity, blood-pressure status, sexual priorities, and the need for faster relief. Avodart works on prostate growth. Alpha-blockers work differently by relaxing smooth muscle around the prostate and bladder neck.
| Treatment approach | Main action | Expected pattern of benefit |
|---|---|---|
| Dutasteride | Lowers DHT and gradually reduces prostate volume | Slower onset; useful when prostate enlargement is a key factor |
| Finasteride | Lowers DHT through type 2 enzyme inhibition | Gradual effect; similar treatment goal with narrower enzyme targeting |
| Alpha-blocker therapy | Relaxes prostate and bladder-neck smooth muscle | Faster urinary symptom relief; does not shrink the prostate |
Finasteride and dutasteride belong to the same drug class, though dutasteride inhibits both major 5-alpha-reductase enzyme types. Alpha-blockers such as tamsulosin may work sooner for flow symptoms, though dizziness, low blood pressure, and ejaculation changes can limit their suitability.
Combination treatment may be used when both rapid symptom relief and long-term reduction of prostate size are needed. The World Health Organization describes 5-alpha-reductase inhibitors and alpha-blockers as established pharmacological approaches for lower urinary tract symptoms associated with BPH in its 2008 model formulary. [3]
In clinical practice, doctors often explain that Avodart is a long-view BPH treatment. A man with a clearly enlarged prostate may benefit from reduced progression risk, but he should not expect a dramatic change after a few doses.
PSA monitoring is one detail that is easy to miss. A lower PSA after starting treatment can be expected, yet any confirmed rise from the new baseline deserves assessment. Doctors also consider sexual function before treatment because pre-existing erectile difficulties, diabetes, cardiovascular disease, smoking, and depression can shape the experience.
Consistency matters because dutasteride works through sustained hormonal suppression. Skipping capsules repeatedly makes it harder to judge whether the treatment is helping.
Older men are among the main groups treated for BPH because prostate enlargement becomes more common with age. Age alone does not rule out treatment, though kidney function, liver health, fall risk, sexual function, PSA history, and other medicines should be reviewed. Follow-up should include symptom review and PSA interpretation when clinically indicated. Health Canada product information published in 2024 supports individualized assessment rather than a one-size-fits-all approach for older adults. Older men using blood-pressure medicines may need extra attention if an alpha-blocker is also prescribed.
No. Avodart capsules should be swallowed whole and should not be split, crushed, chewed, or opened. Damaged capsules can irritate the mouth or throat, while leaking contents pose a pregnancy exposure concern through skin contact. The EMA dutasteride product information, updated in 2023, advises avoiding contact with leaking capsules. If swallowing capsules is difficult, discuss another management approach before starting.
Discuss urinary symptoms, prior PSA values, liver disease, sexual-function concerns, breast symptoms, allergies, and every prescription or non-prescription medicine being used. Mention plans for fathering a child, since dutasteride can affect semen parameters and remains in the body for an extended period. WHO clinical material from 2008 supports assessment for other causes of urinary symptoms before starting long-term BPH therapy. Painful urination, fever, visible blood in urine, or sudden retention require assessment for causes beyond routine BPH.
Changes are usually gradual because treatment reduces DHT-driven prostate growth rather than rapidly relaxing prostate muscle. Some men notice symptom changes after several months, while maximum benefit may take longer. A 2010 Cochrane review of 5-alpha-reductase inhibitors found that these medicines can improve BPH outcomes over months and reduce the risk of progression in appropriate patients. A follow-up plan is more useful than judging the result after only a few weeks.
Reducing evening fluids may decrease night-time urination, while caffeine and alcohol can worsen urgency and frequency in some men. Constipation can aggravate lower urinary tract symptoms, so fibre intake, hydration earlier in the day, and regular activity may help bladder comfort. The Canadian Urological Association guidance published in 2022 includes behavioural measures alongside medicine for men with lower urinary tract symptoms. These habits do not replace the prostate-shrinking action of Avodart, yet they can make daily symptoms easier to manage.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
Avodart is intended for male BPH treatment. It should not be used by women, and exposure during pregnancy must be avoided because suppression of DHT can interfere with normal development of male fetal genitalia.
The concern is strongest with a broken or leaking capsule because the contents can be absorbed through the skin. Intact capsules are designed to keep the contents enclosed.
I used Avodart for several months because my urologist found prostate enlargement despite my age. The first change was less urgency at night, though it took longer than I expected. I noticed lower libido for a while, which was frustrating, but it became less noticeable later.
I had taken the capsules daily for about four months before my stream felt more consistent. Nothing changed in the first few weeks. I liked that I was waking less often, but I had reduced semen volume and needed to discuss that at follow-up.
I had been getting up three or four times nightly before starting treatment. By month six, I was usually up once or twice, and the feeling of incomplete emptying had eased. My PSA follow-up was explained carefully because the result had to be read differently while taking Avodart.
I stopped after several weeks because I felt my erections were less reliable and that affected my relationship. Urinary symptoms had not changed enough by then for me to feel comfortable continuing. My doctor explained that the medicine works slowly, but the side effect mattered more to me.
I took it consistently after my assessment showed enlargement and a weak stream. The improvement was gradual rather than obvious day to day. I made the mistake of thinking it was not working after two months, but my follow-up measurements gave a clearer picture.
